Compare INGN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGN | ALEC |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.1M | 158.8M |
| IPO Year | 2013 | 2019 |
| Metric | INGN | ALEC |
|---|---|---|
| Price | $6.31 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $11.25 | $4.83 |
| AVG Volume (30 Days) | 195.1K | ★ 518.5K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,668,000.00 | $21,045,000.00 |
| Revenue This Year | $8.03 | $2.03 |
| Revenue Next Year | $7.76 | $29.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $5.34 | $1.09 |
| 52 Week High | $9.13 | $3.40 |
| Indicator | INGN | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 41.58 |
| Support Level | $6.00 | $1.37 |
| Resistance Level | $6.73 | $1.60 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 41.79 | 25.44 |
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.